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background: Hirsutism, deﬁned by the presence of excessive terminal hair in androgen-sensitive areas of the female body, is one of
the most common disorders in women during reproductive age.
methods: We conducted a systematic review and critical assessment of the available evidence pertaining to the epidemiology, patho-
physiology, diagnosis and management of hirsutism.
results: The prevalence of hirsutism is 10% in most populations, with the important exception of Far-East Asian women who
present hirsutism less frequently. Although usually caused by relatively benign functional conditions, with the polycystic ovary syndrome
leading the list of the most frequent etiologies, hirsutism may be the presenting symptom of a life-threatening tumor requiring immediate
intervention.
conclusions: Following evidence-based diagnostic and treatment strategies that address not only the amelioration of hirsutism but
also the treatment of the underlying etiology is essential for the proper management of affected women, especially considering that hirsutism
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is, in most cases, a chronic disorder needing long-term follow-up. Accordingly, we provide evidence-based guidelines for the etiological
diagnosis and for the management of this frequent medical complaint.
Key words: hirsutism / androgen excess / terminal hair / polycystic ovary syndrome / guidelines
Introduction
Hirsutism is the medical term that refers to the presence of excessive
terminal (coarse) hair in androgen-dependent areas of the female
body. Especially among young women, hirsutism negatively inﬂuences
psychological well-being (Barth et al., 1993; Sonino et al., 1993). This is
important because hirsutism is among the most frequent medical com-
plaints (Escobar-Morreale, 2010). Although hirsutism generally reﬂects
hormone imbalances, it can rarely be related to a life-threatening
disorder (Escobar-Morreale, 2010).
With the scope of reviewing all published evidence assessing the
epidemiology, pathophysiology, diagnosis and treatment of hirsutism,
and targeting specialist academic centers in which network-based
care involving different subspecialties (i.e. pediatricians, endocrinolo-
gists, internists, gynecologists, dermatologists and nutritionists) is pro-
vided in collaboration with general practitioners, The Androgen Excess
and Polycystic Ovary Syndrome (AE-PCOS) Society appointed a panel
of experts. The charge given to this panel of experts was to develop
evidence-based guidelines to improve long-term management of
hirsutism and the chronic hormonal, reproductive and metabolic
disorders frequently associated with hirsutism.
Methods
Panel
The AE-PCOS Society Board appointed a panel of experts on hirsutism,
selected from those researchers who had authored many original articles
in the ﬁeld. Panel members and Board Directors constituted the Writing
Committee.
Data
Reviews of published peer-reviewed medical literature identiﬁed studies
evaluating hirsutism. Multiple databases were searched, including
MEDLINE, EMBASE, Cochrane, ERIC, EBSCO, dissertation abstracts and
Current Contents. Reviews focused on the epidemiology, pathophysiol-
ogy, diagnosis and treatment of hirsutism. More than 1500 articles were
initially available for review. Some studies were eliminated because data
were not related to the focus of the guidelines, insufﬁcient for epidemio-
logical analysis or reported in previous publications. All data sources were
analyzed recognizing positive publication bias.
Process
The committee critiqued each review before submitting the manuscript to
the AE-PCOS Society Board for approval. Reviews included individual
studies, systematic reviews, hand searches, abstracts, and individual data-
bases and expert data. Each review was conducted by at least two inves-
tigators, and criteria for inclusion/exclusion were agreed upon by at least
two reviewers in each area and arbitrated by a third when necessary. The
position statement applied part of the Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE) group criteria
(Atkins et al., 2004; Swiglo et al., 2008a), in which strength of a rec-
ommendation was indicated ‘recommend’ or a weaker recommendation
was indicated ‘suggest’. Recommendations were made based on evidence
that was considered appropriate in making the recommendation. Insti-
tutional Review Board approval was not obtained because the study
reviewed publicly available medical literature.
Quantiﬁcation and epidemiology
of hirsutism
Several methods are available for the evaluation of hirsutism in
women, including objective and subjective ones. Objective methods
for assessing hair growth (such as photographic evaluations, weighing
of shaved or plucked hairs and microscopic measurements) are
complex, inconvenient and costly, limiting widespread clinical use
(Yildiz et al., 2010). Subjective methods generally refer to visually
scoring the body and facial terminal hair growth in speciﬁed areas
and are potentially subject to inter-observer variation.
Many scoring methods based on visual assessment of hair type and
growth have been proposed, the differences between them relate to
the area of the body being evaluated and whether or not the charac-
teristics of hair are assessed simultaneously (Yildiz et al., 2010). The
landmark study for the visual scoring of hirsutism was conducted in
1951 by Garn (1951); his goal was to assess hairiness in males. He
quantiﬁed the amount of hair using a ﬁve-point scale (0–4) based
on the amount of terminal hair in nine body areas (beard and mous-
tache, hypogastric, thoracic, lower arm and leg, upper arm and leg,
gluteal, lumbosacral, lower back and upper back).
Several hirsutism scores for women (Shah, 1957; Ferriman and
Gallwey, 1961; Moncada, 1970; Hatch et al., 1981; Derksen et al.,
1993; Practice Committee of the American Society for Reproductive
Medicine, 2006) followed the Garn score for men, and applied a
similar 0–4 scale to different areas of the female body that appear
to be the most sensitive and speciﬁc assessment of the action of
androgens on the female pilosebaceous unit (Yildiz et al., 2010).
Of these methods, the modiﬁed Ferriman–Gallwey score (mFG)
proposed by Hatch et al. (1981) has now become the gold standard
for the evaluation of hirsutism (Yildiz et al., 2010). This method
scores 9 of the 11 body areas (upper lip, chin, chest, upper and
lower back, upper and lower abdomen, arm, forearm, thigh and
lower leg) originally proposed by Ferriman and Gallwey (1961),
excluding the lower legs and forearms, which are areas sensitive
to very low androgen concentrations even in healthy women. If
terminal hair growth is not present in the examined area, a score
of zero is given. Minimally visible terminal hair growth is given a
score of 1, a score of 2 is given if hair growth is more than
minimal but not equivalent to that of an adult male, and a score
of 3 is that of a not very hairy male while a score of 4 is that typi-
cally observed in well-virilized healthy adult males (Figs 1 and 2).
Total scores range from 0 to 36. Hirsutism has been usually
graded as mild up to a score of 15, moderate from 16 to 25,
and severe above 25.
Epidemiology, diagnosis and management of hirsutism 147
 at Centro M
arani A
zienda O
spedaliera V
erona on February 22, 2016
http://hum
upd.oxfordjournals.org/
D
ow
nloaded from
 
As the mFG score applies a visual and subjective scale, inter-
observer variation cannot be completely eliminated. Although the
few studies addressing inter-observer variation of the visual scores
of hirsutism had conﬂicting results (Derksen et al., 1993; Wild
et al., 2005; Api et al., 2009), if applied by trained physicians,
these methods yield a fairly good agreement among independent
observers (Derksen et al., 1993; Api et al., 2009). Suggestions to
decrease this variability include requesting patients not to use
laser or electrolysis for at least 3 months, not to depilate or wax
for at least 4 weeks and to avoid shaving for at least 5 days
before the examination (Yildiz et al., 2010). Other helpful measures
include minimizing the number of examiners (Wild et al., 2005),
training the examiners uniformly and using a uniform graphical rep-
resentation of the scoring system (Yildiz et al., 2010). A photo-
graphic representation of the mFG scoring system (Fig. 2) may be
helpful in this regard.
An essential aspect for the diagnosis of hirsutism is the cut-off value
of the mFG score used for its diagnosis. Currently, many clinicians and
researchers choose a mFG score ≥ 8 as indicative of hirsutism. This
cut-off value was selected by Hatch et al. (1981) because only 4.3%
of the reproductive age female population studied by Ferriman and
Gallwey in the UK scored 8 or above for the combined nine body
areas they termed ‘hormonal’ (Ferriman and Gallwey, 1961).
However, because terminal body hair growth has substantial racial
and ethnic variability, the cut-off value of the mFG score should be
ideally established for the population to which it is applied. Table I
includes suggested mFG score cut-off values for different races and
ethnicities based on the 95th percentile value of unselected women
of reproductive age.
However, it must be kept in mind that the mFG scoring system gives
an estimation of the total amount of body hair, and not that of the
regional distribution of the excessive hair growth. The latter might
also occur only in a few areas—particularly the face—without exceed-
ing the cut-off value in the total hirsutism score (Yildiz et al., 2010).
Furthermore, a considerable number of women with androgen
excess disorders may present with normal body hair; hence the
absence of hirsutism does not exclude consideration of such a dis-
order in women with other features of androgen excess, such as
acne, alopecia, infertility or menstrual dysfunction (Yildiz et al., 2010).
In addition to being one of the most frequent medical complaints
among young women, hirsutism is also one of the most prevalent
health problems in women of reproductive age that can signiﬁcantly
and negatively impact on their quality of life (Sonino et al., 1993).
Table II summarizes several studies addressing the prevalence of hir-
sutism in unselected populations of women worldwide. The actual
prevalence of hirsutism ranges from 4.3 to 10.8% in Blacks and
Whites, but appears to be somewhat lower in Asians (Table II).
The very large prevalence of hirsutism reported by a few studies
may represent an overestimation resulting from self-referral bias
(Diamanti-Kandarakis et al., 1999; March et al., 2010) and from the
fact that the hirsutism score was self-reported by the patients
(March et al., 2010).
Accordingly, the committee recommends the routine use of the
nine body areas mFG score to quantify hirsutism, and recommends
Figure 1 Schematic representation of the mFG score. Nine body areas (upper lip, chin, chest, arm, upper abdomen, lower abdomen, upper back,
lower back and thighs) are scored from 1 (minimal terminal hairs present) to 4 (equivalent to a hairy man). If no terminal hairs are observed in the
body area being examined the score is zero (left blank). Clinically, terminal hairs can be distinguished from vellus hairs primarily by their length (i.e.
.0.5 cm) and the fact that they are usually pigmented. Reproduced with permission from R. Azziz (Yildiz et al., 2010). Copyright Oxford University
Press, 2010.
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establishing a cut-off value to deﬁne hirsutism as the 95th percentile of
the mFG score of the relevant general population ethnicity and age. If
this value is unavailable, we suggest that a cut-off value of 8 or above
be applied to White and Black women, while for Far East and South
East Asian women this be decreased to three or above.
Pathophysiology of hirsutism
Hair, especially on the scalp and face among humans, is important for
social and sexual communication. There are 5 million hair follicles
covering the human body with 100 000 located on the scalp (Paus
and Foitzik, 2004). Hair covers human skin with the exception of
the glabrous skin of lips, palms and soles. Very few new hair follicles
are formed after birth, and the number of hair follicles begins to
decrease after the age of 40 years (Uno, 1986).
Structurally, there are three types of hair: lanugo is a soft hair
densely covering the skin of the fetus, which disappears within the
ﬁrst months of post-partum life; vellus hairs are soft but larger
than lanugo hairs, are usually non-pigmented, and are generally
,0.03 mm in diameter; and terminal hairs are longer, pigmented
and coarser in texture. Eyebrows, eyelashes, scalp hair and pubic
and axillary hair in both sexes, and much of the body and facial hair
in men, are composed of terminal hairs (Uno, 1986).
Hair arises from the hair follicle, a highly dynamic organ that has the
ability to regenerate; the hair cycle consists of rhythmic repetitive
growth, regression and tissue-remodeling events (Girman et al.,
1998). Clinically relevant hair growth disorders represent undesirable
alterations of the hair follicle cycle: prolongation of the hair growth
phase (anagen) is observed when vellus hairs evolve into terminal
hairs (e.g. in hirsutism), whereas shortening of the anagen phase
leads to hair loss.
Structure of the hair follicle
Hair follicles consist of several components. The most superﬁcial part
of the hair follicle extends from the sebaceous duct to the epidermal
surface. This portion includes the hair canal and the distal outer root
sheath. The tubular connection between the epidermal surface and
the distal part contains the hair shaft (Fig. 3). The outer root
sheath is contiguous with the basal epithelial layer. The inner root
Figure 2 Photographs depicting facial and body terminal hair
growth scored according to the mFG method. All were taken on
women who had not used laser or electrolysis for at least
3 months, not depilated or waxed for at least 4 weeks, not shaved
or plucked for at least 5 days before the photograph. The photo-
graphs depict scores of 1 through 4 for the upper lip (A), chin (B),
chest (C), upper abdomen (D), lower abdomen (E), arm (F),
thighs (G) upper back (H) and lower back (I). The areas were photo-
graphed with a standard single-lens reﬂex camera (Nikon N50, Nikon
Corp, Melville, NY, USA) equipped with a macro lens (Vivitar 50 or
100 mm Auto Focus Macro, Vivitar Corp, Newbury Park, CA, USA)
and ring ﬂash (Vivitar Macroﬂash 5000, Vivitar Corp). For ﬁlm, Koda-
color VR 200 ISO ﬁlm (Eastman Kodak Co, Rochester, NY, USA) was
used. Representative areas were selected. All photographs of hair
were anonymized and all identifying information removed, meeting
current Institutional Review Board for Human Use and Health Insur-
ance Portability and Accountability Act of 1996 standards. Modiﬁed
with permission from R. Azziz (Yildiz et al., 2010). Copyright
Oxford University Press, 2010.
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sheath is a multilayered rigid tube that is composed of terminally dif-
ferentiated hair follicle keratinocytes, surrounded by the outer root
sheath. It provides the conduit for the hair to exit at the skin
surface, and the hair shaft itself (Headington, 1984; Fuchs et al.,
2001). The skin hairs are keratinized epithelial cells organized in a
ﬂexible cylinder that differ in color, thickness and length. Keratin pro-
teins form the hair shaft that grows within the outer hair root sheath
in the epidermis (Fig. 3).
The sebaceous gland is an acinar gland composed of lipid-ﬁlled
sebocytes, localized close to the insertion of the arrector pili
muscle. The sebaceous gland secretes sebum to the epidermal
surface via a holocrine mechanism. Sebum helps to make hair and
skin waterproof. The arrector pili muscle is a tiny smooth muscle
that connects the hair follicle with the dermis, and causes, when con-
tracted, the raising of the hair. Together with the hair follicle and the
arrector pili muscle, the sebaceous gland forms the pilosebaceous
unit.
The bulge is a protrusion of the outer root sheath located below
the sebaceous gland at the insertion site of the muscle arrector pili.
The bulge contains the hair follicle stem cells. The bulb is a thickening
of the proximal end of the hair follicle, which contains undifferentiated
matrix, melanocytes and outer root sheath cells. The dermal papilla,
consisting of closely packed specialized mesenchymal ﬁbroblasts, is a
mesodermal signaling system within the hair follicle (Schneider et al.,
2009). The dermal papilla produces numerous paracrine factors that
inﬂuence the size and color of the hair produced.
Hair follicle morphogenesis
In humans, organization of the primitive epidermis takes place
between 9 and 12 weeks of embryonic life. The master switch for
hair follicle development involves canonical Wnt/b-catenin signaling
that is essential for hair follicle fate at least in mice (Andl et al.,
2002). Communication between the developing epidermis and under-
lying mesenchyme plays a key role in hair differentiation as well as
other ectodermal appendages, such as nails, teeth, feathers and
scales. Additional factors modulating this communication include
members of the hedgehog protein, transforming growth factor-b,
bone morphogenetic protein, ﬁbroblast growth factor and tumor
necrosis factor families (Andl et al., 2002; Schneider et al., 2009).
The hair follicle growth cycle
The hair follicle functions as a stem cell repository containing cells of
multiple cell lineages (Kligman, 1959; Paus and Foitzik, 2004). To some
extent, the molecular oscillator system responsible for hair cycling is
autonomous, as demonstrated by persistent hair cycling following
transplantation to a different skin site (Ebling, 1988). The presence
of these stem cells is crucial to continued hair follicle cycling.
Hair follicles pass through three major growth phases (Fig. 4). These
three phases are anagen (a stage of rapid growth), telogen (a stage of
relative quiescence) and catagen (apoptosis-mediated regression). Fol-
lowing regression of the epithelial column during catagen, the dermal
papilla relocates to lie near the bulge (Schneider et al., 2009). The
physical proximity of these two structures promotes stem cell acti-
vation and initiation of a new hair cycle. Following activation, the
stem cells leave the bulge and proliferate downward to generate the
outer root sheath (Hsu et al., 2011). During anagen, rapidly proliferat-
ing progenitor cells in the bulb generate the hair shaft and its surround-
ing inner root sheath, and the distance between the bulge and dermal
papilla increases. The duration of the anagen phase governs the hair
cycle length in different body regions. Scalp follicles have the longest
anagen phase, and most normal scalp follicles are in the anagen
phase (Randall, 2008). Although often not obvious, seasonal altera-
tions occur in the human hair cycle with more hair shedding during
the autumn months (Randall, 2008).
.............................................................................................................................................................................................
Table I Suggested cut-offs for themFG hirsutism score according to the 95 percentile in different unselected populations
of premenopausal women.
Author, year Year Country Race Ethnicity Sample size Suggested
mFG cut-offa
Tellez and Frenkel (1995) 1995 Chile White Hispanic 236 ≥6
Asuncion et al. (2000) 2000 Spain White Mediterranean 154 ≥8
Sagsoz et al. (2004) 2004 Turkey White Middle Eastern 204 ≥9
Cheewadhanaraks et al. (2004) 2004 Thailand Asian Thai and Chinese 531 ≥3
DeUgarte et al. (2006) 2006 USA White Caucasian and Hispanic 283 ≥8
Black African-American 350 ≥8
Zhao et al. (2007) 2007 China Asian Chinese Han 623 ≥2
Api et al. (2009) 2009 Turkey White Middle Eastern 121 ≥11
Moran et al. (2010) 2010 Mexico White Hispanic 150 ≥10
Noorbala and Kefaie (2010) 2010 Iran White Middle Eastern 900 ≥10
Kim et al. (2011) 2011 Korea Asian Chinese 1010 ≥6
Gambineri (2011, personal communication) 2011 Italy White Mediterranean 200 ≥9
Escobar-Morreale (2011, personal communication) 2011 Spain White Mediterranean 291 ≥10
aAs deﬁned by the 95th percentile of an unselected population of premenopausal women.
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The perpetual rhythm of the hair growth cycle is reminiscent of
other cyclic biological processes in which distinct clock mechanisms
have been studied. CLOCK and BMAL1 are transcription factors
that regulate circadian rhythms. RNA microarray data obtained from
mouse hair and skin indicated that genes associated with cell cycle
and DNA/RNA metabolism were up-regulated in the early anagen
phase (Lin et al., 2009). Although no morphological abnormalities
were found in hair follicles, delayed anagen progression was found
in mice transgenic for mutations in the CLOCK or BMAL1 genes
(Lin et al., 2009). Additional details regarding the role of clock genes
will likely be elucidated in the future.
Androgens and hair growth
The growth of sexual hair is mainly dependent on the presence of
androgens. Before puberty, vellus hair is small, straight and fair with
undeveloped sebaceous glands. In response to the increased levels
of androgens during puberty, the vellus follicles in pubic and axillary
areas of boys and girls develop into terminal hairs that are larger,
curlier and darker (Reynolds, 1951; Marshall and Tanner, 1969).
Similarly, the development of facial hair, male pattern pubic hair and
trunk hair in men is attributed to androgen stimulation (Hamilton,
1958). In other body areas, such as the forehead and the cheeks,
androgens increase the size of the sebaceous glands, but the hair in
these areas remains vellus. These speciﬁc differentiation patterns
remain unexplained, suggesting that androgens have paradoxically
different effects on human hair follicles depending on their body site
(Randall, 2008).
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Figure 3 Schematic histomorphology of the terminal hair follicle.
Sagittal section through a human scalp hair follicle showing the infun-
dibulum, the hair shaft and the bulb. Note that bulge is located in a
protrusion of the outer root sheath just below the sebaceous gland
at the insertion site of the muscle arrector pili, and contains the
hair follicle stem cells. Bulb is a thickening of the proximal end of
the hair follicle, and encloses proliferating matrix cells, melanocytes
and outer root sheath cells surrounding the dermal papilla, which is
a mesodermal signaling system of the hair follicle.
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Androgens may be generated via a de novo synthetic pathway from
cholesterol to testosterone and dihydrotestosterone (DHT), and/or
via a shortcut pathway from circulating dehydroepiandrosterone-sulfate
(DHEAS). The de novo synthesis of androgens requires four ‘upstream’
proteins, including steroidogenic acute regulatory protein, cytochrome
P450 cholesterol side-chain cleavage enzyme, cytochrome P450
17a-hydroxylase/17,20-lyase and steroid 3b-hydroxysteroid dehydro-
genase, which are responsible for the early steps of androgen synthesis
from cholesterol to dehydroepiandrosterone. Additional ‘downstream’
enzymes, including 17b-hydroxysteroid dehydrogenase and 5a-
reductase, catalyze the conversion of androstenedione into testoster-
one and, subsequently, to DHT, amplifying its androgenic effects
(Chen and Zouboulis, 2009).
The major androgens in the serum of normal cycling women are
DHEAS, dehydroepiandrosterone, androstenedione, testosterone
and DHT, in descending order of serum concentrations (Burger,
2002). Testosterone and DHT bind to the androgen receptor to
promote changes in gene transcription. Dehydroepiandrosterone,
DHEAS and androstenedione do not bind to the androgen receptor
and can be considered to be pro-hormones.
Sulfotransferase, principally sulfotransferase 2A1, catalyzes the
conversion of dehydroepiandrosterone to DHEAS in the adrenal
cortex. Steroid sulfates can be hydrolyzed to the native steroid by
steroid sulfatase. Circulating testosterone in women originates
mostly (50%) by peripheral conversion of other steroids, the rest
coming in equal parts (25%) from the ovaries and the adrenals
(Longcope, 1986). Of note, the most active androgen, DHT, is syn-
thesized locally in androgen target tissues in a step catalyzed by the
enzyme 5a-reductase, and its circulating levels are very low (Long-
cope, 1986).
Adrenal pubertal maturation, adrenarche, is characterized by
increasing DHEAS concentrations. The physical manifestation of
adrenarche is pubarche, the development of sexual hair. Adrenarche,
a phenomenon limited to a fewer higher primate species, is associ-
ated with increased 17,20-lyase activity of cytochrome P450
17a-hydroxylase/17–20 lyase, decreased 3b-hydroxysteroid dehy-
drogenase type 2 activity and increased expression of cytochrome
b5 (Auchus and Rainey, 2004). This change in DHEAS synthesis is
independent of the hypothalamic–pituitary–gonadal axis (Sklar
et al., 1980; Counts et al., 1987). While adrenocorticotropic
hormone (ACTH) plays a permissive role, the molecular events trig-
gering the onset of adrenarche remain uncertain (Miller, 2009).
Onset of adrenarche prior to age 8 years in girls, premature adre-
narche, can precede the development of PCOS in some, but not
all, girls. In addition to the effects of circulating androgens on the
growth of sexual hair, human sebaceous glands and hair follicles
are equipped with all the necessary enzymes for biosynthesis and
metabolism of androgens (Thiboutot et al., 2003). Therefore, circu-
lating androgen levels may not reﬂect local androgen concentrations
at the pilosebaceous unit (Chen and Zouboulis, 2009).
Furthermore, cutaneous androgen effects also depend on the
expression of the androgen receptor in the pilosebaceous unit
(Chen and Zouboulis, 2009). Androgen receptor expression and
activity have been demonstrated mainly in epidermal keratinocytes,
sebaceous glands and hair dermal papilla cells, with restricted
expression in dermal ﬁbroblasts, sweat gland cells, endothelial cells
and genital melanocytes.
In sebaceous glands, androgen receptor immunoreactivity is
detected only in the basal, early differentiated sebocytes. Conﬂicting
data exist regarding the exact pattern of androgen receptor expression
in human hair follicles, especially concerning expression in occipital
scalp. Androgen receptor expression is found mainly in the dermal
papilla but is absent in the keratinocytes of outer root sheath (includ-
ing the bulge regions supposed to contain the hair stem cells) and
Figure 4 The hair follicle growth cycle. Hair follicles possess the ability, unique among mammalian tissues, to be partially regenerated in a process
termed the hair follicle growth cycle. Hair follicles go through repeated cycles of development and growth (anagen), regression (catagen) and rest
(telogen) to enable the replacement of hairs.
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those of the inner root sheaths (Fig. 3). On the other hand, higher
levels of androgen receptor immunoreactivity are found in the
dermal papilla cells from balding hair follicles when compared with
non-balding scalp.
Both testosterone and DHT bind to the androgen receptor with
high afﬁnity. Polymorphisms in the androgen receptor gene also inﬂu-
ence the activity of the receptor. Reports about the association of
these polymorphisms with androgen-dependent skin disorders, includ-
ing hirsutism and male pattern baldness, have been inconsistent
(Sawaya and Shalita, 1998; Calvo et al., 2000).
Hirsutism reﬂects the interaction between circulating androgen con-
centrations, local androgen concentrations and the sensitivity of the
hair follicle to androgens. Yet, the severity of hirsutism does not cor-
relate well with circulating androgen concentrations. Furthermore, the
hair follicle response to circulating androgens varies considerably
within and between individuals, explaining why some women with
clearly elevated androgen levels do not show cutaneous manifes-
tations, or may have seborrhea, acne or alopecia in the absence of
clinically relevant hirsutism.
Finally, hirsutism must be distinguished from hypertrichosis, an
excessive growth of vellus hair that results from either heredity or
from the use of drugs, such as glucocorticoids, phenytoins, minoxidil
or cyclosporine, in which hair is distributed in a generalized, non-
sexual pattern, and is not caused by excess androgen (although hyper-
androgenism may aggravate this condition). Furthermore, although
estrogens modulate the hair cycle, they appear to have no direct
effects on hair growth.
Diagnosis of hirsutism
Etiological diagnosis
After establishing the presence of hirsutism by an increased mFG
score, or if a history of hirsutism is strongly suggested by the ﬁnding
of some evidence of terminal hair in androgen-dependent areas in
women successfully treated for this condition, diagnostic studies
should focus on identiﬁcation of the most likely etiology.
The importance of performing an extensive evaluation in women
presenting even with mild hirsutism is based on the fact that the sever-
ity of hirsutism does not correlate well with the magnitude of andro-
gen excess (Reingold and Rosenﬁeld, 1987; Pfeifer et al., 1989;
Carmina and Lobo, 2001; Legro et al., 2010). Minimal unwanted
hair growth and mild hirsutism in women can provide important indi-
cators of an underlying androgen excess disorder (Souter et al., 2004;
Di Fede et al., 2010). In fact, even severely hyperandrogenemic
patients with PCOS or non-classic congenital adrenal hyperplasia
(NCCAH) may not have hirsutism and, in contrast, women with
severe idiopathic hirsutism may have entirely normal circulating andro-
gen concentrations without evidence of ovarian dysfunction. In some
patients, previous treatment of hirsutism may interfere with the
current estimation of the mFG score, yielding a falsely low hirsutism
score. The occurrence of metabolic disorders and cardiovascular
risk markers in women with hirsutism correlates with the severity of
hyperandrogenemia (Azziz et al., 2006, 2009; Wild et al., 2010).
Finally, speciﬁc etiologies, such as NCCAH, are associated with signiﬁ-
cant heritable risks that entail genetic counseling (Speiser et al., 2000).
Therefore, we recommend establishing the etiology of hirsutism in all
patients irrespective of its severity, especially in patients referred for
the initial evaluation of this complaint.
Functional causes account for most hirsutism cases. The evolution
of the criteria for diagnosis of polycystic ovary syndrome (PCOS)
(Zawadzki and Dunaif, 1992; The Rotterdam ESHRE/ASRM-
sponsored PCOS consensus workshop group, 2004; Azziz et al.,
2006, 2009) has determined important consequences on the classiﬁ-
cation of the androgen excess disorders. In fact, both European
Society of Human Reproduction and Embryology/American Society
of Reproductive Medicine (The Rotterdam ESHRE/ASRM-sponsored
PCOS consensus workshop group, 2004) and the AE-PCOS Society
(Azziz et al., 2006, 2009) diagnostic criteria consider that women
with hyperandrogenism and polycystic ovarian morphology but with
normal ovulatory cycles have PCOS. These patients need to be
separated from the group of hyperandrogenic patients with normal
ovulatory cycles and normal ovarian morphology who may be con-
sidered to have idiopathic hyperandrogenism (Azziz et al., 2000;
Carmina, 2006a, b).
Patients with hirsutism but normal circulating androgens, normal
ovulatory cycles and normal ovaries may be considered a separate
group, termed idiopathic hirsutism (Azziz et al., 2000). A putative
increase in the conversion of testosterone into DHT and/or an
increased androgen receptor sensitivity have been proposed as the
mechanisms explaining hirsutism in these women (Azziz et al.,
2000). However, these women may share mild steroidogenic abnorm-
alities with women presenting with the full hyperandrogenic pheno-
types (Escobar-Morreale et al., 1997) that are not detected by the
diagnostic tools usually available in clinical practice.
In fact, some experts believe that, because of the many problems
in deﬁning the normal androgen range with commercial assays (see
below), hirsute patients who have normal ovulatory cycles and
normal ovaries should be included in the group of idiopathic hyperan-
drogenism irrespective of their serum androgen concentrations
(Carmina, 2006b). While idiopathic hyperandrogenism and idiopathic
hirsutism constitute two separate disorders (Azziz et al., 2000), only
accurate testosterone assays may permit differentiation between
these two conditions.
NCCAH caused by 21-hydroxylase or 11b-hydroxylase deﬁciencies
is a less common but still important cause of hirsutism in certain popu-
lations. Women with classic congenital adrenal hyperplasia (CAH) may
develop hirsutism if their replacement glucocorticoid doses are too
low or because of poor adherence. Androgen-secreting tumors are
rare but should always be considered in the initial diagnostic approach
to hirsutism because of the potential for signiﬁcant and grave
consequences.
Although hirsutism is typically not the major concern, other
uncommon disorders associated with hirsutism include gestational
hyperandrogenism, drug-induced hirsutism, Cushing’s syndrome, glu-
cocorticoid resistance, acromegaly and hyperprolactinemia. Among
these disorders, the diagnosis is usually evident from other signs
and symptoms (Escobar-Morreale, 2010). In some studies (Azziz
et al., 2004), patients with severe insulin resistance and acanthosis
nigricans (HAIR-AN) have been considered a separate group, but
most authors include these patients within the PCOS spectrum of
disorders.
Therefore, we recommend considering ﬁve main androgen-excess
disorders in the diagnostic approach to patients with hirsutism:
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(i) PCOS, when women present with clinical and/or biochemical
hyperandrogenism together with ovulatory dysfunction and/or
polycystic ovarian morphology.
(ii) Idiopathic hyperandrogenism, when women present with clinical
and biochemical hyperandrogenism but have regular ovulatory
cycles of normal length and normal ovarian morphology.
(iii) Idiopathic hirsutism, when women present with hirsutism but
have normal androgen concentrations, ovulatory cycles and
normal ovarian morphology.
(iv) NCCAH.
(v) Androgen-secreting tumors.
PCOS is the most common disorder associated with hyperandrogen-
ism. Analysis of large series shows that PCOS is present in about 70%
of patients (Table III). Most patients have the classic anovulatory form,
while the ovulatory form is relatively less common but still present in
almost 20% of PCOS patients (Carmina et al., 2006).
The problem of milder causes of hirsutism, such as idiopathic hyper-
androgenism and idiopathic hirsutism, should not be underestimated.
In fact, because classic PCOS is present in 6% of women of repro-
ductive age (Asuncion et al., 2000; Azziz et al., 2004), the prevalence
of these milder androgenic disorders may be calculated to occur in
approximately another 2% of adult women.
Clinical history and physical examination
Adetailed clinical history including family history and a complete physical
examination remain the most valuable tool to determine the etiology of
the hirsutism. Functional causes almost always show a peripubertal
onset and a slow progression over years, a family history of hyperandro-
genism is frequent, and signs of virilization (such as clitoromegaly or
balding) or of defeminization (such as mammary atrophy) are extremely
rare (Escobar-Morreale, 2010). In contrast, androgen-secreting tumors
usually manifest with sudden onset and rapid progression; severe viriliza-
tion and defeminization usually accompany the hirsutism (Escobar-
Morreale, 2010). However, tumors producing only moderately exces-
sive androgen may have indolent presentations (Rosenﬁeld, 2005).
Moreover, clinical evaluation provides valuable clues to discriminate
between functional causes of hirsutism: oligo- or amenorrhea and
infertility may indicate the ovarian dysfunction associated with
PCOS, NCCAH or even androgen-secreting tumors. Since PCOS is
frequently associated with insulin resistance, abdominal obesity and/
or acanthosis nigricans are frequent physical ﬁndings (Escobar-
Morreale, 2010).
Hormone proﬁle
Although hirsutism is an unequivocal marker of excessive androgen
action at the pilosebaceous unit, as stated earlier, the severity of
hirsutism correlates poorly with the severity of androgen excess
(Reingold and Rosenﬁeld, 1987; Pfeifer et al., 1989; Carmina and
Lobo, 2001; Legro et al., 2010). This apparent paradox possibly indi-
cates that hirsutism not only reﬂects circulating androgen levels but is
also inﬂuenced by the peripheral metabolism of androgens (Goodarzi
et al., 2006), by the sensitivity of target tissues to androgens (Sawaya
and Shalita, 1998) and by other hormonal variables, including insulin
resistance and compensatory hyperinsulinism (Landay et al., 2009).
Yet this paradox might also result from signiﬁcant variability among
many of the commercial direct immunoassays used for serum andro-
gen measurements. Several Societies have recently questioned the use
of direct immunoassays for the measurements of serum androgen
levels in children and women in favor of more sensitive methods
that couple extraction by liquid chromatography with tandem mass
spectrometry (LC/MS) (Rosner et al., 2007; Azziz et al., 2009).
Nevertheless, some total testosterone immunochemiluminescence
assays provide reliable values with functional sensitivities similar to
that of LC/MS-based methods (Ognibene et al., 2000; Kushnir
et al., 2010). Recent data indicate that currently available commercial
total testosterone LC/MS-based assays for measuring circulating
total testosterone levels in patients with PCOS in a clinical setting
may not be superior to a commercial direct radioimmunoassay
(Legro et al., 2010).
Until ongoing projects aimed to standardize testosterone testing
result in improved cost-effective assays (Rosner and Vesper, 2010),
the issue of which serum androgen should be measured in hirsute
patients and how these steroids must be assayed remains controver-
sial, to the extreme that some experts suggest not measuring serum
.............................................................................................................................................................................................
Table III Frequencies of the etiologies of androgen excess in large clinical series.
Author, year Sample
size (n)
PCOS
(n)
Idiopathic
hyperandrogenism (n)
Idiopathic
hirsutism (n)
NCCAH
(n)
Tumors
(n)
Miscellaneous
(n)
Azziz et al. (2004) 873 749a 59b 39 18 2 6
Glintborg et al. (2004) 340 134 86b 115 2 1 2
Unluhizarci et al. (2004) 168 96 29b 27 12 3 1
Carmina et al. (2006) 950 685c 150 72 41 2 0
Escobar-Morreale et al. (2008) 270 171 61b 24 6 0 8
Total no. (%) 2601 (100) 1835 (71) 385 (15) 277 (10) 79 (3) 8 (0.3) 17 (0.7)
NCCAH, non-classic congenital adrenal hyperplasia; PCOS, polycystic ovary syndrome.
aThe original article considered 33 patients with the hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN) syndrome as a separate disorder from PCOS, reducing
this ﬁgure to 716.
bPolycystic ovarian morphology was not considered for the diagnosis of PCOS in these studies, which relied on the 1990 National Institute of Child Health and Human Development
criteria (Zawadzki and Dunaif, 1992). Some of these patients might have been diagnosed with PCOS if ovarian morphology had been considered.
cThis study considered polycystic ovarian morphology for PCOS diagnosis, and 147 of the 685 PCOS patients who had regular ovulatory cycles would have been included in the
idiopathic hyperandrogenism subgroup if ovarian morphology had not been considered.
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androgens levels at all, at least in women presenting with mild hirsut-
ism (Martin et al., 2008).
Based on our perspective that measuring serum androgens and
other steroid concentrations are essential for establishing the etiology
of hirsutism and that the magnitude of the increase in serum androgen
levels may correlate with the metabolic and cardiovascular associ-
ations of functional causes of hyperandrogenism, including PCOS
(Wild et al., 2010), while recognizing the limitations of current andro-
gen assays, we suggest to proceed as follows:
(i) Obtain at least one determination of serum androgen levels in
every patient with hirsutism before starting any treatment that
might interfere with such measurements.
(ii) Of all the circulating androgens, assessments of free testosterone
levels are much more sensitive than the measurement of total
testosterone for the diagnosis of hyperandrogenic disorders
(Azziz et al., 2009). Free testosterone measurements ideally
require equilibrium dialysis techniques, and should never rely
on direct analog radioimmunoassays, which are notoriously inac-
curate (Rosner, 2001).
(iii) A high-quality direct double antibody radioimmunoassay for total
testosterone might be useful clinically, as long as the inter-assay
coefﬁcients of variation are below 10% as determined by the
laboratory conducting the assays, and the normal ranges are
determined in-house in a carefully selected healthy non-
hyperandrogenic control female population. Alternatively, a
greater degree of accuracy, particularly for clinical research, may
be possibly obtained by measuring total testosterone concen-
tration using LC/MS techniques (Azziz et al., 2009).
(iv) The diagnostic performance of measuring serum total testoster-
one may be enhanced easily by the concomitant measurement of
sex hormone-binding globulin (SHBG), permitting the calculation
of free testosterone levels that have a fairly good concordance
and correlation with free testosterone as measured by the equi-
librium dialysis methods (Vermeulen et al., 1999). In this regard,
single determinations of serum SHBG and free testosterone
levels have a high predictive value for PCOS in epidemiologic
studies, with receiver operating characteristic curve values
above 0.830 (Escobar-Morreale et al., 2001). Serum SHBG may
also provide a surrogate marker of insulin resistance in women
(Pugeat et al., 1996) and therefore its measurement may be
useful per se.
(v) The value of also measuring serum androstenedione and DHEAS
levels in patients with hirsutism is unclear (Azziz et al., 2009).
Measuring androstenedione may increase the number of subjects
identiﬁed as hyperandrogenemic by 10% (Azziz et al., 2009),
whereas increased DHEAS concentrations may be the sole
abnormality in circulating androgens in 10% of hyperandrogenic
patients. Nonetheless, we should note that DHEAS levels might
not always reﬂect the status of adrenocortical steroidogenesis,
and overinterpretation of DHEAS levels should be avoided
(Azziz et al., 2009).
(vi) Less-frequent etiologies of hirsutism must be excluded in order to
accurately establish the etiology. All patients presentingwith hirsut-
ism should be screened for androgen-secreting tumors, even if
screening is primarily clinical as stated earlier. It should be noted
that overreliance on androgen levels as a screening tool will lead
to signiﬁcant false positive rates (Azziz et al., 2009). Hyperprolac-
tinaemia is an uncommon cause of hirsutism but prolactin should
be measured if features of menstrual irregularity or galactorrhea
are present. NCCAH is more common in certain ethnic groups
where its screening may be mandatory, but routine assessment
of 17-hydroxyprogesterone or 11-deoxycortisol will depend on
the prevalence of the condition in the community, accessibility of
the assay and the expense incurred. Accurate serum prolactin
determination requires avoidance of stress related to venipuncture
and other situations that may falsely increase its serum levels.
17-hydroxyprogesterone measurements should be obtained
early in the morning (Azziz et al., 1999). Importantly, the normal
ranges for serummarkers of these disorders should be established
in-house (Escobar-Morreale et al., 2008) and must be followed by
further testing in case of doubt, including exclusion ofmacroprolac-
tinemia by precipitation of serum with polyethylene-glycol before
assaying for prolactin (Escobar-Morreale, 2004) or conducting
full adrenal stimulation with the synthetic ACTH, cosyntropin
(Azziz et al., 2009). Where indicated, identiﬁcation of women
with 21-hydroxylase deﬁcient NCCAH is important because of
the beneﬁts of genetic counseling; such women are often hetero-
zygous carriers for at least one CYP21A2 mutation associated
with classic CAH (Speiser et al., 2000; Escobar-Morreale et al.,
2008). In addition, the prevalence of having a child with classic
CAH is higher than predicted based on population frequency of
mutation bearing CYP21A2 alleles (Moran et al., 2006). Finally, clini-
cal screening is usually adequate to exclude rare causes of hirsut-
ism, such as drugs, gestational hyperandrogenism, acromegaly
and Cushing’s syndrome.
Ovulatory function
Assessment of ovulatory function is essential to determine the precise
etiology, and is also useful to identify patients with hirsutism who are
at risk for metabolic and cardiovascular dysfunction, which is increased
in women with PCOS, especially when accompanied by obesity (Wild
et al., 2010). We recommend:
(i) Obtaining a detailed menstrual history dating back to puberty: a
chronic history of oligomenorrhea—menstrual cycles longer than
35 days for at least six cycles per year—or amenorrhea—lack of
menstrual discharge for three consecutive theoretical menstrual
cycles—is suggestive of chronic ovulatory dysfunction.
(ii) Because as many as 15–40% of patients with hirsutism present
with regular but anovulatory menstrual cycles (Azziz et al.,
1998), the occurrence of ovulation should be documented using
either basal body temperature charts, luteal phase serum pro-
gesterone concentrations or both. The cut-off values of serum
progesterone levels indicative of ovulation must be established
in-house.
Metabolic proﬁle
For patients with hirsutism and other signs suggestive of classic PCOS,
we recommend following the metabolic evaluation proposed in the
AE-PCOS guidelines for the assessment of glucose tolerance (Salley
et al., 2007) and cardiovascular risk (Wild et al., 2010) in women
with PCOS that include:
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(i) Assessment of waist circumference and BMI.
(ii) Complete lipid proﬁle, including total cholesterol, low-density
lipoprotein-cholesterol, non-high-density lipoprotein (HDL)-
cholesterol, HDL-cholesterol and triglycerides.
(iii) A 2-h post 75-g oral glucose challenge to assess glucose toler-
ance. A few members of the task force recommend conducting
this test only in patients with obesity or in lean patients with
additional risk factors such as advanced age (.40 years), per-
sonal history of gestational diabetes or family history of type 2
diabetes mellitus.
(iv) Standard clinical blood pressure determination.
The evidence for an association of metabolic and cardiovascular dys-
function in women with milder forms of hyperandrogenism, such as
idiopathic hyperandrogenism or idiopathic hirsutism, remains indeter-
minate. Current evidence suggests the existence of a graded spectrum
of risk depending on the etiology of hirsutism, with higher risk corre-
sponding to women with classic PCOS followed by those with ovula-
tory PCOS and idiopathic hyperandrogenism, and the lowest risk for
women with idiopathic hirsutism (Carmina, 2006a, b; Welt et al.,
2006; Barber et al., 2007; Shroff et al., 2007; Goverde et al., 2009).
Until additional data become available, we suggest conducting a
limited evaluation of metabolic and cardiovascular dysfunction in
women with milder hyperandrogenic disorders, including clinical
measurements of obesity, abdominal adiposity and blood pressure.
A more complete evaluation, including a lipid proﬁle and indexes of
glucose tolerance and insulin resistance, should be restricted to
women with obesity, abdominal adiposity or other cardiovascular
risk factors (Carmina, 2006a).
Ultrasound evaluation
Ultrasonography is helpful in the investigation of hirsutism, along with
clinical ﬁndings and hormonal assays. The main role of ultrasound
evaluation is to detect the presence of polycystic ovarian morphology,
although this ﬁnding may be fortuitously associated with other
disorders, such as NCCAH or androgen-secreting tumors.
We recommend using the criteria used in the ESHRE/ASRM
(The Rotterdam ESHRE/ASRM-sponsored PCOS consensus work-
shop group, 2004) and AE-PCOS Society (Azziz et al., 2006, 2009)
deﬁnitions of polycystic ovarian morphology: presence of either 12
or more follicles measuring 2–9 mm in diameter and/or increased
ovarian volume (.10 ml) (Balen et al., 2003). In developing these cri-
teria, priority was placed on ovarian volume and the follicle number
because both are physical entities that can be measured in real-time
conditions. Both ovarian volume and follicle number are considered
to be key and consistent features of polycystic ovarian morphology.
The consensual threshold to discriminate a normal ovary from a
polycystic ovary is 12 or more follicles of 2–9 mm diameter. This
threshold was shown as being the best compromise between the
most complete studies, up to 2003. With continuing improvement
in image resolution, this threshold may need to be redeﬁned since fol-
licles ,2 mm in diameter can now be detected and counted with the
latest generation of ultrasound equipment.
Recently, when using new ultrasound equipment and applying the
2003 threshold, a major but artiﬁcial increase in the prevalence of
asymptomatic polycystic ovaries was observed in normal populations,
especially in women younger than 30 years (Duijkers and Klipping,
2010; Johnstone et al., 2010; Kristensen et al., 2010). This led some
authors to conclude recently that polycystic ovarian morphology has
no pathological signiﬁcance (Johnstone et al., 2010). Furthermore,
the consensual volume threshold to discriminate a normal ovary
from a polycystic ovary is 10 ml (Balen et al., 2003), but more
recent studies (Carmina et al., 2005; Jonard et al., 2005) suggest
that decreasing the threshold to 7.0–7.5 ml may be more appropriate
in some populations. Until evidence using newer ultrasound tech-
niques leads to an updated consensus, we suggest establishing the
threshold values for the antral follicle count and ovarian volume indica-
tive of polycystic ovarian morphology at each center.
Finally, Fig. 5 provides an algorithm for the diagnosis of hirsutism
according to the recommendations of the panel of experts.
Management of hirsutism
Hirsutism is a clinical sign and is not a disease by itself, and its presence
does not necessarily require treatment. However, perception of
having male-type pattern body hair, irrespective of its objective sever-
ity, may have profound adverse effects on the psychological wellbeing
of women with even mild hirsutism. Therefore, the subjective percep-
tion of the patient, and not only the absolute extent of hair growth,
should guide physicians in deciding whether hirsutism should be
treated or not.
The goals of the correct management of hirsutism are to ameliorate
the hirsutism and reproductive complaints, to prevent and/or treat
the possible associated metabolic derangements and, if possible, to
treat the underlying cause (Escobar-Morreale, 2010).
Important principles for the management of hirsutism are listed as
follows (Escobar-Morreale, 2010). It may be helpful to discuss these
principles with affected women at the onset of therapy.
(i) Treatment will never be curative and therefore, chronic treat-
ment will likely be necessary.
(ii) The effects of drugs are not evident before several months of
administration.
(iii) Treatment should take into account the characteristics and
expectations of the individual patient.
(iv) Treatment must be monitored by an expert.
Cosmetic measures are usually effective in controlling mild hirsutism,
especially when terminal hair localizes in the most exposed areas
such as the face. However, when hirsutism is moderate to severe
and/or is widespread in androgen-sensitive areas, a pharmacological
approach is usually required. On the other hand, drugs are only par-
tially effective on terminal hairs. Therefore, management of clinically
important hirsutism is based upon a dual approach: pharmacological
therapy to reduce androgen secretion and/or androgen action, and
removal of terminal hair already present.
Life-style modiﬁcation
Life-style management, including promotion of physical exercise and
dietary advice, is essential for the management of androgen excess
and for the cardiovascular protection in women with PCOS (Azziz
et al., 2009; Wild et al., 2010). However, even when there is evidence
for a reduction in total and free testosterone and an increase in SHBG
concentrations after successful life-style modiﬁcation, no convincing
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data support a reduction in hirsutism following such measures (Moran
et al., 2011).
Yet because some data suggest that the rate of attenuation of hir-
sutism may be slower when treatments aim at reducing androgen
levels (Spritzer et al., 1990), the effects of life-style changes could
have been less noticeable because of the usually short duration of
the studies evaluating such effects. On the other hand, lack of substan-
tial effects over an extended period may greatly affect compliance with
treatment and cannot be ignored.
Therefore, we suggest offering life-style recommendations to
women presenting with hirsutism, especially when PCOS is the
most probable underlying etiology but only after explaining that such
measures are unlikely to ameliorate hirsutism and will likely need
additional approaches. Among life-style recommendations, smoking
cessation should be strongly encouraged because this habit exacer-
bates the undesirable effects of many of the drugs available for
hirsutism and related conditions (Luque-Ramirez et al., 2009).
Cosmetic measures
Cosmetic hair removal complements medical treatment. In mild or
localized cases, cosmetic methods may be sufﬁcient as a single
therapy.
Traditional cosmetic methods include bleaching, plucking, shaving,
waxing, chemical treatment and electrolysis. Of these, only galvanic
electrolysis, alone or ‘blended’ with thermolysis, may destroy the
dermal papilla (Kligman and Peters, 1984), resulting in permanent
amelioration of hirsutism in the treated area (Richards and Meharg,
1995). If competently performed, electrolysis does not result in scar-
ring or other cosmetic side-effects, although transitory side-effects,
such as discomfort, postinﬂammatory erythema, occasional whealing
or even small crusts, may develop (Richards and Meharg, 1995).
The application of an eutectic mixture of local anesthetics prior to
the procedures improves tolerance, whereas shaving 1–5 days
before electrolysis ensures that only growing anagen hairs are epilated,
increasing the efﬁcacy of the procedure (Richards and Meharg, 1995).
The other traditional methods are safe and do change the rate of hair
growth but should be used ideally in combination with pharmacologi-
cal intervention. Local discomfort is the common shortcoming of these
procedures (Escobar-Morreale, 2010).
Newer methods include laser therapy and intense pulsed light. The
available lasers operate in the red or near-infrared wavelengths and
rely on selective photothermolysis, in which the melanin pigment in
the follicle absorbs the selected wavelength leading to hair follicle
destruction (Sanchez et al., 2002). This explains why, in general,
laser hair removal is most successful in patients with lighter skin
colors and dark colored hairs (Sanchez et al., 2002).
A systematic review (Haedersdal and Gotzsche, 2006) of 11 RCTs
comparing laser with control treatments, involving more than 400
patients, noticed long-term hair reduction in only one trial using alex-
andrite laser therapy (Hussain et al., 2003) while short-term beneﬁts
were seen in several others (Haedersdal and Gotzsche, 2006).
Several non-randomized studies have suggested the efﬁcacy of laser
and intense pulsed light hair removal over the long-term (Haedersdal
and Wulf, 2006). Among available photoepilation techniques, alexan-
drite and diode lasers appear to be more effective than intense pulsed
light, neodymium:YAG or ruby lasers (Sanchez et al., 2002; Haeders-
dal and Wulf, 2006). Laser-based photoepilation is safe, easy to
perform and side-effects are rare and transitory (Sanchez et al.,
2002; Haedersdal and Wulf, 2006).
Based on these considerations we recommend:
(i) Using bleaching and temporary methods of hair removal, such as
shaving, plucking, waxing or the use of chemical depilatory agents,
in the ﬁrst months of treatment while waiting for drug treatment
Figure 5 Algorithm for the etiological diagnosis of hirsutism. 1–24 ACTH, cosyntropin; 17-OHP, 17-hydroxyprogesterone; CT, computed tom-
ography; MR, magnetic resonance; NCCAH, non-classic congenital adrenal hyperplasia.
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to be noticed, or even as single treatment in milder cases. The
patient must be assured that shaving does not increase the
growth and thickness of hair, which is a common misbelief
among patients because the blunt tip of shaved hair is more
visible than the tapered tip of uncut hair.
(ii) Using galvanic or blended electrolysis for localized areas, such as
the face, as single procedure or as an adjuvant to pharmacological
intervention but only if an experienced operator is available
because inexperienced electrolysis may cause considerable local
side-effects or even scarring.
(iii) Using alexandrite or diode laser photoepilation for generalized
hirsutism, as the single procedure in mild cases, or as an adjuvant
to pharmacological intervention in patients presenting with mod-
erate or severe hirsutism, or in those requiring such treatment
for associated conditions.
Pharmacological intervention
Drug treatment of hirsutism is limited to patients with hirsutism who
are not seeking immediate fertility. Evidence-based information
regarding the pharmacological treatment of hirsutism is scarce. The
vast majority of available literature on the issue is constrained by
several major limitations, in particular by the lack of blinded and objec-
tive assessment of effects of treatments, small sample sizes and short
duration of trials in relation to the physiology of hair growth. In
addition, the individual response to treatment may be variable.
These limitations make it difﬁcult to establish a scale of relative efﬁcacy
of different drugs and even to prove the real efﬁcacy of these
medications.
Topical eﬂornithine
A 13.9% eﬂornithine cream is licensed for use in the topical treatment
of unwanted facial hair (Barman Balfour and McClellan, 2001). Eﬂor-
nithine, a drug initially developed for the treatment of trypanosomal
sleeping sickness, is an irreversible inhibitor of L-ornithine decarboxy-
lase, an enzyme that catalyzes the conversion of ornithine to
putrescine, a polyamine that is critical to the regulation of cell
growth and differentiation within the hair follicle (Barman Balfour
and McClellan, 2001). Continuous topical administration of eﬂor-
nithine cream reversibly slows facial hair growth in up to 70% of
patients treated, signiﬁcantly improving and reducing the psychological
burden of facial hirsutism (Jackson et al., 2007; Wolf et al., 2007; Lapi-
doth et al., 2010). However, eﬂornithine is not approved for the treat-
ment of unwanted terminal hair in areas other than the face, and its
cost is relatively high. The problem that limits the possibility of using
eﬂornithine cream in larger skin areas is linked to the possibility of
undesirable effects in the case of signiﬁcant systemic absorption.
We suggest the use of topical eﬂornithine for facial hirsutism as a
single procedure only in mild cases, or as an adjuvant to permanent
or long-term depilation (Hamzavi et al., 2007) or to medical treatment
with oral drugs (Escobar-Morreale, 2001).
Oral contraceptive pills
Oral contraceptive pills (OCPs) contain estrogen plus progestin and
have been the mainstay for hirsutism therapy for decades. OCPs
suppress ovarian androgen synthesis via inhibition of gonadotrophin
secretion from the pituitary, and the estrogen compound increases
SHBG concentrations markedly, thereby suppressing free testosterone
levels to values that—in some cases—may fall even below the
lower limit of the normal range for adult women (Luque-Ramirez
et al., 2007).
The decrease in circulating free androgens results in an improve-
ment in the hirsutism, provided that OCPs are administered chroni-
cally (Porcile and Gallardo, 1991). Even if large long-term placebo-
controlled RCTs assessing the actual efﬁcacy of OCPs for hirsutism
are lacking, subjective improvement in hirsutism with OCPs ranges
from 60 to 100% (Raj et al., 1982; Dewis et al., 1985; Guido et al.,
2004). Such an improvement may decrease hirsutism scores to
within the normal range in women presenting with mild hirsutism, sup-
porting the use of an OCP as the single drug in these cases. Moreover,
several studies documented improvement in hair growth using
objective measures (Casey et al., 1966; Cullberg et al., 1985; Dewis
et al., 1985; Venturoli et al., 1999; Guido et al., 2004; Batukan and
Muderris, 2006).
Among the different formulations, low-dose OCPs containing a
neutral (low androgenicity) progestin, such as desogestrel or gesto-
dene, or an antiandrogen, such as cyproterone acetate, chlormadi-
none acetate or the spironolactone-derivative drospirenone, are of
choice for the treatment of hirsutism because all of these drugs
provide adequate normalization of testosterone levels (Sobbrio
et al., 1990; Porcile and Gallardo, 1991; Coenen et al., 1996). If the
clinical response to OCPs containing a neutral progestin is unsatisfac-
tory, changing the OCP formulation to include an antiandrogenic
progestin may be useful.
Of note, these low-dose third-generation OCP formulations are not
associated with the unfavorable metabolic proﬁle of older formu-
lations, and may even have beneﬁcial effects on the lipid proﬁle
(Vermeulen and Rubens, 1988) even among obese insulin-resistant
patients with PCOS (Lemay et al., 2006; Luque-Ramirez et al., 2007).
However, a mild increase in blood pressure might occur with some
of these newer OCP formulations (Luque-Ramirez et al., 2007;
Kriplani et al., 2010). Especially among smokers, the third-generation
OCPs may have deleterious effects on coagulation (Luque-Ramirez
et al., 2009) and may increase the risk of non-fatal venous throm-
boembolism compared with second-generation OCPs containing the
androgenic progestin levonorgestrel (Kemmeren et al., 2001; van
Hylckama Vlieg et al., 2009; Jick and Hernandez, 2011; Parkin et al.,
2011). Although the increased risk of venous thromboembolism
with third-generation OCPs is small, it must be noted that even
older formulations containing androgenic progestins may also amelio-
rate hirsutism (Breitkopf et al., 2003). However, these older OCPs
may be less effective on hirsutism and might increase BMI, compared
with OCPs containing neutral progestins (Sanam and Ziba, 2011).
Therefore, the choice of an OCP for the treatment of hirsutism
must balance carefully the greater efﬁcacy of third-generation pills
against the safer coagulation proﬁle of second-generation OCP,
especially in adolescents, hypertensive women and smokers.
Aside from the amelioration of hirsutism, OCPs provide the effec-
tive contraception recommended for the concomitant use of antian-
drogens, and are quite useful for the regularization of menstrual
bleeding in women with PCOS (Escobar-Morreale, 2010), which will
also reduce the risk of endometrial hyperplasia.
Based on these considerations, we recommend prescribing a
low-dose neutral or antiandrogenic OCP as ﬁrst-line therapy for
hirsutism:
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(i) As a single drug in women with mild hirsutism.
(ii) As an adjuvant to antiandrogen administration in women with
moderate or severe hirsutism and to provide adequate contra-
ception to these patients.
(iii) To guarantee regular menstrual bleeding in hirsute patients with
PCOS presenting with oligo- or amenorrhea.
Antiandrogens
Antiandrogens (androgen receptor blockers and 5a-reductase inhibi-
tors) are possibly the most effective drugs for hirsutism, although
the evidence supporting this statement is relatively weak (Swiglo
et al., 2008b).
Several RCTs, summarized in Table IV, support the use of antian-
drogens for hirsutism. All these drugs ameliorate hirsutism compared
with placebo. In a 6 month double-blind, placebo-controlled study
carried out in 40 women with PCOS or idiopathic hirsutism, ﬂutamide
250 mg/day, ﬁnasteride 5 mg/day or spironolactone 100 mg/day
were all more effective than placebo on hirsutism, as assessed by
changes in hair shaft diameter, hirsutism score and self-evaluation by
the patients (Moghetti et al., 2000a). Furthermore, the combination
of a triphasic oral contraceptive and ﬂutamide was more effective
than the oral contraceptive alone in a 1 year double-blind, placebo-
controlled multicentre trial, carried out in 119 hirsute women (Calaf
et al., 2007). Similarly, the combination of an oral contraceptive con-
taining 2 mg of cyproterone acetate and either spironolactone 100 mg,
ﬁnasteride 5 mg or cyproterone acetate 100 mg was better than the
oral contraceptive alone in three 1 year double-blind studies (Belisle
and Love, 1986; Kelestimur and Sahin, 1998; Sahin et al., 1998).
However, at present there is not enough information to establish a
scale of efﬁcacy for these drugs. Some comparative studies did not ﬁnd
differences in efﬁcacy between antiandrogen drugs (Wong et al., 1995;
Grigoriou et al., 1996; Falsetti et al., 1997; Fruzzetti et al., 1999;
Moghetti et al., 2000a; Spritzer et al., 2000; Beigi et al., 2004),
whereas in other studies ﬂutamide appeared to have the greatest efﬁ-
cacy, and ﬁnasteride the lowest, of antiandrogens (Cusan et al., 1994;
Erenus et al., 1997; Sahin et al., 1998; Falsetti et al., 1999; Pazos et al.,
1999; Venturoli et al., 1999). Furthermore, these drugs do not appear
to exert dose-dependent effects against hirsutism (Barth et al., 1991;
Muderris et al., 1997; Bayram et al., 2002; Tartagni et al., 2004; Calaf
et al., 2007).
Among approaches combining several antiandrogens, the combi-
nation of spironolactone with ﬁnasteride was more effective than spir-
onolactone alone in two small 6-month studies carried out in women
with PCOS or idiopathic hirsutism (Unluhizarci et al., 2002; Kelestimur
et al., 2004).
It must be stressed that antiandrogens cannot be given to pregnant
women for the risk of feminization of male fetuses and should only be
prescribed to women using secure contraception. Unless oral or trans-
dermal (Henzl and Loomba, 2003) contraceptives are contraindicated,
antiandrogens should be given in combination with these drugs
(Kuttenn et al., 1980), especially cyproterone acetate and spironolac-
tone. These medications may cause menstrual disturbances or even
amenorrhea when given alone because of their strong progestin
effects. If hormonal contraception is contraindicated, for instance in
women at risk for thrombophilia or in heavy smokers older than 35
years, contraception must be assured by use of an intrauterine
device or by surgical sterilization (Escobar-Morreale, 2010) before
using antiandrogens.
Another consideration for antiandrogens is the potential for signiﬁ-
cant side-effects. In particular, the non-steroidal antiandrogen ﬂuta-
mide (Castelo-Branco et al., 2009) is associated with an increased
risk for severe or even fatal liver toxicity; this risk was below 0.5%
in large populations of male subjects with prostate cancer, given the
higher amounts of the drug than those used for hirsutism (Wysowski
et al., 1993; Manso et al., 2006). In hirsute women, severe liver toxicity
is anecdotic but has been reported to occur with doses as low as
250 mg/day (Manso et al., 2006; Castelo-Branco and Del Pino,
2009). Finally, with the exception of cyproterone acetate and spirono-
lactone in some countries, antiandrogens are not approved for the
treatment of hirsutism and are used off-label after adequate informed
consent.
In summary, we recommend prescribing an antiandrogen:
(i) Combined with OCPs in women presenting with moderate or
severe hirsutism, or in those with a milder hirsutism who do
not reach a satisfactory control of hair growth using OCPs alone
after 1 year of treatment.
(ii) As single drugs in women in whom OCPs are contraindicated,
warranted that a reliable contraceptive method is used.
Considering their similar efﬁcacy and potential for side-effects, we
suggest prescribing ﬁnasteride, cyproterone acetate or spironolactone
instead of ﬂutamide when an antiandrogen is needed, although the
latter is apparently safe at doses below250 mg/day (Ibanez et al., 2005).
Insulin sensitizers
Insulin sensitizers are widely used for PCOS because insulin resistance
contributes to the pathogenesis of this disorder (Azziz et al., 2009).
Insulin sensitizers improve insulin resistance and menstrual dysfunction
and may decrease serum androgen concentrations (Lord et al., 2003);
their effects on hirsutism are much less clear.
In recent years, several placebo-controlled comparisons of insulin
sensitizer drugs for the treatment of hirsutism were published: nine
used metformin (Moghetti et al., 2000b; Pasquali et al., 2000; Kelly
and Gordon, 2002; Gambineri et al., 2004; Hoeger et al., 2004;
Maciel et al., 2004; Onalan et al., 2005; Gambineri et al., 2006;
Romualdi et al., 2010), whereas one involved pioglitazone (Aroda
et al., 2009) and another used troglitazone (Azziz et al., 2001), a thia-
zolidinedione that is no longer available in the market because of its
hepatic side-effects. Of note, hirsutism was not the main outcome
measure in any of these studies. Most of the studies with metformin
found effects on hirsutism that were similar to placebo, whereas tro-
glitazone (Azziz et al., 2001) and pioglitazone (Aroda et al., 2009)
induced small but statistically signiﬁcant decreases in the hirsutism
score compared with placebo (Table V).
Compared with OCPs and antiandrogens, metformin does not
appear to be more effective for the treatment of hirsutism. Mixed
results were observed when comparing metformin with OCPs (Morin-
Papunen et al., 2000; Harborne et al., 2003; Morin-Papunen et al.,
2003; Allen et al., 2005; Lemay et al., 2006; Luque-Ramirez et al.,
2007; Meyer et al., 2007; Hoeger et al., 2008). Most studies used a
combination of ethinylestradiol and low-dose cyproterone acetate,
and in approximately half of them the OCP was more effective com-
pared with the insulin-sensitizer (Table V). However, the short length
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Table IV Summary of RCTs comparing the efﬁcacy of different antiandrogen drugs on hirsutism.
Author, year Blinding Months Sample
size
Disorders Regimens compareda Outcome Efﬁcacy on hirsutism
Belisle and Love (1986) Double 12 158 Hirsutism (1) Diane
(2) Diane + CPA 100
mFG Diane + CPA. Diane
(mFG . 14)
McLellan et al. (1989) Double 9 22 Hirsutism (1) Spironolactone 100
(2) Placebo
Diameter No difference
Self-evaluation
Barth et al. (1991) Double 12 38 Hirsutism (1) Diane
(2) Diane + CPA 20
(3) Diane + CPA 100
mFG No difference
Hair diameter
Linear growth
Cusan et al. (1994) Single 9 53 Hirsutism (1) Flutamide 500 mg +OCP
(2) Spironolactone 100 + OCP
mFG Flutamide +OCP . Spironolactone +OCP
(mFG . 13)
Ciotta et al. (1995) Single 9 18 PCOS (1) Finasteride 7.5
(2) Placebo
mFG Finasteride. Placebo
Idiopathic hirsutism
Wong et al. (1995) None 6 14 Hirsutism (1) Spironolactone 100
(2) Finasteride 5
mFG No difference
(mFG . 11) Hair diameter
Self-evaluation
Grigoriou et al. (1996) None 9 22 Idiopathic hirsutism (1) CPA 100
(2) Flutamide 500
mFG No difference
Erenus et al. (1997) Single 9 40 Idiopathic hirsutism (1) Spironolactone 100
(2) Finasteride 5
mFG Spironolactone. Finasteride
(mFG . 10)
Falsetti et al. (1997) None 6 44 PCOS (1) Finasteride 5
(2) Flutamide 500
mFG No difference
(mFG 11–24) Hair diameter
Muderris et al. (1997) Single 12 65 Hirsutism (1) Flutamide 250
(2) Flutamide 500
mFG No difference
Kelestimur and Sahin (1998) Single 12 50 Hirsutism (1) Diane
(2) Diane + Spironolactone 100
mFG Diane + Spironolactone. Diane
(mFG . 8)
Sahin et al. (1998) Single 9 42 PCOS (1) Diane
(2) Finasteride 5
mFG Diane . Finasteride
Idiopathic hirsutism
Falsetti et al. (1999) None 12 110 PCOS (1) Finasteride 5
(2) Flutamide 500
mFG Flutamide. Finasteride
Idiopathic hirsutism
(mFG 11–23)
Hair diameter
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Fruzzetti et al. (1999) Single 12 45 Hirsutism (1) Finasteride 5
(2) CPA 25+ EE 0.020
(3) Flutamide 500
mFG No difference
Pazos et al. (1999) None 9 33 Functional ovarian
hyperandrogenism
(1) GnRHa+ OCP
(2) CPA 100 +OCP
(3) Flutamide 500 + OCP
mFG Flutamide. (CPA ¼ GnRHa)
Idiopathic hirsutism
Venturoli et al. (1999) None 12 66 PCOS (1) Flutamide 250
(2) Finasteride 5
(3) Ketoconazole 300
(4) 3) CPA 12.5 + EE 0.010–0.020
mFG (CPA ¼ Flutamide) . Finasteride
Idiopathic hirsutism Hair diameter Ketoconazole 50% drop out rate
NCCAH Linear growth
De Leo et al. (2000) None 6 35 PCOS (1) GnRHa
(2) GnRHa + Diane
(3) GnRHa + Flutamide 250
mFG No difference
Moghetti et al. (2000a) Double 6 40 Hirsutism (1) Spironolactone 100
(2) Finasteride 5
(3) Flutamide 250
(4) Placebo
mFG
Hair diameter
Self-evaluation
(Spironolactone ¼ Finasteride ¼
Flutamide). Placebo
Muderris et al. (2000) Single 12 70 Hirsutism (1) Flutamide 250
(2) Finasteride 5
mFG Flutamide. Finasteride
(mFG . 8)
Spritzer et al. (2000) None 12 44 PCOS (1) Spironolactone 200
(2) CPA 50 + EE 0.035
mFG No difference
Idiopathic hirsutism
(mFG 11–35)
Tartagni et al. (2000) Single 6 50 PCOS (1) Diane
(2) Diane + Finasteride 5
mFG Diane + Finasteride . Diane
Idiopathic hirsutism Self-evaluation
Sahin et al. (2001) Single 12 40 Hirsutism (1) Diane
(2) Diane + Finasteride 5
mFG Diane + Finasteride . Diane
Bayram et al. (2002) None 12 46 PCOS (1) Finasteride 2.5
(2) Finasteride 5
mFG No difference
Idiopathic hirsutism
(mFG . 12)
Taner et al. (2002) None 6 84 Hirsutism (1) Flutamide 250
(2) Flutamide 250 + Diane
mFG No difference
Unluhizarci et al. (2002) Single 6 34 PCOS (1) Spironolactone 100
(2) Spironolactone
100 + Finasteride 5
mFG Spironolactone + Finasteride. Spironolactone
Idiopathic hirsutism
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Table IV Continued
Author, year Blinding Months Sample
size
Disorders Regimens compareda Outcome Efﬁcacy on hirsutism
Lakryc et al. (2003) Double 6 24 PCOS (1) Finasteride 5
(2) Placebo
mFG Finasteride. Placebo
Idiopathic hirsutism Self-evaluation
Beigi et al. (2004) None 9 40 PCOS (1) Finasteride 5
(2) CPA 25 + EE 0.020
mFG No difference
Idiopathic hirsutism
Ganie et al. (2004) None 6 69 PCOS (1) Spironolactone 50
(2) Metformin 1000
mFG Spironolactone. Metformin
Kelestimur et al. (2004) Single 12 65 PCOS (1) Spironolactone 100
(2) Spironolactone
100 + Finasteride 5
mFG Spironolactone + Finasteride. Spironolactone
Idiopathic hirsutism
Tartagni et al. (2004) Single 10 38 PCOS (1) Finasteride 2.5 once daily
(2) Finasteride 2.5 every 3 days
mFG No difference
Idiopathic hirsutism
(mFG . 10)
Gambineri et al. (2006) Single 12 76 PCOS (1) Diet
(2) Diet+ Metformin 1700
(3) Flutamide 500
(4) Diet + Metformin
1700 + Flutamide 500
mFG (Flutamide ¼ Flutamide + Metformin).
(metformin + diet ¼ diet)
Calaf et al. (2007) Double 12 119 PCOS (1) OCP
(2) Flutamide 125 + OCP
(3) Flutamide 250 + OCP
(4) Flutamide 375 + OCP
mFG Flutamide (125 ¼ 250 ¼ 375) +OCP.OCP
Idiopathic hirsutism
(mFG . 15)
CPA, cyproterone acetate; Diane, cyproterone acetate 2 mg plus ethinylestradiol 35 mg; EE, ethinylestradiol; mFG, modiﬁed Ferriman–Gallwey score; GnRHa, GnRH analog; OCP, oral contraceptive pill.
aDoses are mg per day unless stated otherwise.
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Table V Summary of RCTs of interventions with insulin sensitizers for hirsutism.
Author, year Blinding Months Sample size Disorders Regimens compareda Outcome Efﬁcacy on hirsutism
Insulin sensitizers versus placebo
Moghetti et al. (2000b) Double 6 23 PCOS (1) Metformin 1500
(2) Placebo
mFG No difference
Pasquali et al. (2000) Double 6 20 PCOS (1) Diet + Metformin 1700
(2) Diet + Placebo
FG Metformin. placebo
Azziz et al. (2001) Double 11 410 PCOS (1) Troglitazone 150, 300 and 600
(2) Placebo
mFG Troglitazone 600. placebo
Kelly and Gordon (2002) Double 6 16 PCOS (1) Metformin 1500
(2) Placebo
FG
Hair growth
Self-assessment
Metformin. placebo
Metformin. placebo
Metformin. placebo
Gambineri et al. (2004) Single 6 20 PCOS (1) Diet + Metformin 1700
(2) Diet + Placebo
FG No difference
Hoeger et al. (2004) Double 11 18 PCOS (1) Metformin 1700
(2) Placebo
mFG No difference
Maciel et al. (2004) Double 6 34 PCOS (1) Metformin 1500
(2) Placebo
FG No difference
Onalan et al. (2005) Double 6 139 PCOS (1) Metformin 1700
(2) Placebo
FG No difference
Gambineri et al. (2006) Single 12 40 PCOS (1) Diet + Metformin 1700
(2) Diet + Placebo
FG No difference
Aroda et al. (2009) Unclear 6 28 PCOS (1) Pioglitazone 45
(2) Placebo
FG Pioglitazone . placebo
Romualdi et al. (2010) Double 6 28 PCOS (1) Metformin 1000
(2) Placebo
FG Metformin. placebo
Insulin sensitizers versus OCPs
Morin-Papunen et al. (2000) None 6 18 PCOS (1) Metformin 1000  2000
(2) Diane
FG Diane. Metformin
Harborne et al. (2003) Unclear 12 52 PCOS (1) Metformin 1500
(2) Diane
FG
Hair diameter
Self-assessment
Metformin. Diane
No difference
Metformin. Diane
Morin-Papunen et al. (2003) None 6 20 PCOS (1) Metformin 1000  2000
(2) Diane
FG Diane. Metformin
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Table V Continued
Author, year Blinding Months Sample size Disorders Regimens compareda Outcome Efﬁcacy on hirsutism
Allen et al. (2005) None 6 35 PCOS (1) Metformin 1000
(2) Norgestimate 0.25 + EE 0.035
mFG No difference
Lemay et al. (2006) None 6 28 PCOS (1) Rosiglitazone 4
(2) Diane
FG Diane. Rosiglitazone
Luque-Ramirez et al. (2007) None 6 34 PCOS (1) Metformin 1700
(2) Diane
mFG Diane. Metformin
Meyer et al. (2007) None 6 110 PCOS (1) Metformin 2000
(2) Diane
(3) Levonorgestrel 0.100 + EE
0.020 + Spironolactone 100
FG No difference
Hoeger et al. (2008) Double 6 43 PCOS (1) Metformin 1700
(2) Desogestrel 0.15 + EE 0.030
(3) Life-style modiﬁcation
(4) Placebo
FG No difference
Metformin and thiazolidinediones
Yilmaz et al. (2005) Single 6 96 PCOS (1) Metformin 1700
(2) Rosiglitazone 4
FG Rosiglitazone .Metformin
Ortega-Gonzalez et al. (2005) None 6 52 PCOS (1) Metformin 2550
(2) Pioglitazone 30
FG No difference
Dereli et al. (2005) None 8 40 PCOS (1) Rosiglitazone 2
(2) Rosiglitazone 4
mFG Rosiglitazone 4 . Rosiglitazone 2
Metformin versus antiandrogens
Ganie et al. (2004) None 6 69 PCOS (1) Spironolactone 50
(2) Metformin 1000
mFG Spironolactone. Metformin
Gambineri et al. (2004) Single 6 20 PCOS (1) Metformin 1700
(2) Flutamide 500
FG Flutamide. Metformin
Gambineri et al. (2006) Single 12 76 PCOS (1) Diet
(2) Diet + Metformin 1700
(3) Diet + Flutamide 500
(4) Diet + Metformin 1700 + Flutamide 500
mFG (Flutamide ¼
Flutamide + Metformin).
(metformin + diet ¼ diet)
aDoses are mg per day unless stated otherwise.
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of these studies precludes reaching any deﬁnite conclusion on the
possible long-term effects of both families of drugs.
A few trials compared antiandrogens with metformin for hirsutism
(Table V). Overall, metformin was less effective compared with ﬂuta-
mide and spironolactone (Ibanez et al., 2002; Gambineri et al., 2004,
2006; Ganie et al., 2004). Also, compared with antiandrogens, the
effect of metformin on hirsutism may require longer periods of
therapy to be noticeable (Gambineri et al., 2006). Very few studies
(Dereli et al., 2005; Ortega-Gonzalez et al., 2005; Yilmaz et al., 2005)
compared the effects on hirsutism of the different insulin sensitizers
available.
Therefore, we recommend against the use of metformin or other
insulin sensitizers as therapy for hirsutism as its possible effects are
unconvincing and possibly not superior to placebo.
Other drugs
There are inconsistent reports regarding the role of glucocorticoids in
the treatment of hirsutism and concerns about their safety (Steinber-
ger et al., 1990). In addition, there is considerable controversy about
the regimen and the most appropriate dosage (Horrocks and London,
1987; Rittmaster and Givner, 1988; Steinberger et al., 1990). The
studies currently available in patients with adrenal (Frank-Raue et al.,
1990; Spritzer et al., 1990) or unselected hyperandrogenism (Emans
et al., 1988; Prezelj et al., 1989; Carmina and Lobo, 1998) and in
women with idiopathic hirsutism (Devoto et al., 2000) suggest that
glucocorticoids are less effective on hirsutism compared with OCPs
or antiandrogens. However, in women with NCCAH, prolonged
remission after withdrawal of antiandrogen therapy may be obtained
by the addition of glucocorticoids (Carmina and Lobo, 1998).
The adrenal enzyme inhibitor ketoconazole ameliorates hirsutism
(Martikainen et al., 1988; Akalin, 1991) but its frequent side-effects
limit its use (Venturoli et al., 1999) to subjects with Cushing’s
syndrome while waiting for deﬁnite therapy.
GnRH analogs are potent inhibitors of ovarian steroidogenesis but
experience with these drugs in the management of hirsutism is quite
limited (van der Spuy and Tregoning, 2008). Considering that these
drugs induce a reversible menopause requiring combined use with
OCPs and its very high economic cost, this class of drugs should
be restricted, if used at all, to the very selected patients with
severe hyperandrogenism of ovarian origin that do not respond to
other drugs.
We therefore recommend against the use of glucocorticoids, keto-
conazole and GnRH analogs for ﬁrst-line therapy of hirsutism because
their effects are generally limited. In addition, other drugs are safer
and/or more cost-effective.
Follow-up
As stated earlier, treatment of hirsutism must be monitored by
an experienced physician. The assessment of treatment efﬁcacy is
mostly clinical and should include an objective measure of the ameli-
oration of hirsutism by repeating the mFG score as well as considering
patient’s satisfaction.
The usefulness of measuring serum androgen levels is less clear,
albeit conﬁrming a decrease in serum androgen levels may increase
patient’s conﬁdence with the efﬁcacy of treatment in women with
hyperandrogenemia, especially while waiting for the clinical response
to be evident. When using OCPs, it is important to measure not
only total testosterone but also SHBG, as these drugs induce a
marked increase in SHBG concentrations that may increase serum
total testosterone levels (Escobar-Morreale, 2010). Measuring serum
androgen levels is not useful in patients treated with antiandrogens
as single drugs.
Figure 6 Algorithm for the management of hirsutism. OCP, oral contraceptive pill.
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Any change in treatment in response to an unsatisfactory result
must consider the length of the terminal hair cycle; the effects of
drug treatment must only be assessed after at least 6 months of con-
tinuous therapy and, ideally, assessment of the clinical response should
ideally wait for at least 1 year after any change in drug treatment.
Finally, Fig. 6 provides an algorithm for the management of hirsutism
according to the recommendations of the panel of experts.
Concluding remarks
Hirsutism is one of the most common disorders affecting women
during the reproductive years. Although often caused by relatively
benign functional conditions, hirsutism may be the presenting
symptom of a life-threatening tumor requiring immediate intervention.
In contrast to the previous guidelines (Martin et al., 2008), we
recommend applying the diagnostic and therapeutic strategies
described here even to patients with mild hirsutism, because the
severity of hirsutism does not correlate well with the magnitude of
androgen excess and because PCOS and NCCAH may be found in
a signiﬁcant number of such patients (Di Fede et al., 2010). In most
cases, hirsutism is a chronic disorder beneﬁting from long-term
follow-up. The use of evidence-based strategies to improve the hirsut-
ism and to treat the underlying disorder is essential for the proper
management of women with hirsutism.
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